Personalized Medicine Partnering Terms and Agreements -





Published: November 2014 | Edition: 7 | Pages: 1289

 

Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 1000 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of personalized medicine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms. The chapter also includes deal trends by big pharma and most active of all biopharma.

                    

Chapter 3 provides a review of the leading biomarker deals since 2009 by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a review of the leading companion diagnostic deals since 2009 by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 5 provides a review of the leading pharmacogenomics deals since 2009 by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 6 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of personalized medicine deals including biomarker, companion diagnostic, pharmacogenomics, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 8 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 9 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 10 provides a comprehensive and detailed review of personalized medicine partnering deals signed and announced since January 2009. The chapter is organized by specific personalized medicine, biomarkers, companion diagnostics and pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by personalized medicine partnering company A-Z , deal type, and therapy type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by personalized medicine partnering company A-Z , deal type, and therapy type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

  

Report scope 

 

Personalized Medicine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to personalized medicine trends and structure of deals entered into by leading companies worldwide.

 

Personalized Medicine Partnering Terms and Agreements includes:

 

o Trends in personalized medicine dealmaking in the biopharma industry since 2009

o Analysis of personalized medicine deal structure

o Access to headline, upfront, milestone and royalty data and contract documents

o Case studies of real-life personalized medicine deals

o Access to over 1000 personalized medicine deal announcements

o The leading personalized medicine deals by value since 2009

o Most active personalized medicine dealmakers since 2009

o The leading personalized medicine partnering resources In Personalized Medicine Partnering Terms and Agreements, the available contracts are listed by:

o Company A-Z

o Headline value

o Stage of development at signing

o Deal component type

o Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Personalized Medicine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1000 personalized medicine deals. Analyzing actual contract agreements allows assessment of the following:

 

o What are the precise personalized medicine rights granted or optioned?

o What is actually granted by the agreement to the partner company?

o What exclusivity is granted?

o What is the payment structure for the deal?

o How are sales and payments audited?

o What is the deal term?

o How are the key terms of the agreement defined?

o How are IPRs handled and owned?

o Who is responsible for commercialization?

o Who is responsible for development, supply, and manufacture? o How is confidentiality and publication managed?

o How are disputes to be resolved?

o Under what conditions can the deal be terminated?

o What happens when there is a change of ownership?

o What sublicensing and subcontracting provisions have been agreed?

o Which boilerplate clauses does the company insist upon?

o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

o Which jurisdiction does the company insist upon for agreement law?

 

 

Executive Summary 

Chapter 1 – Introduction
 

Chapter 2 – Trends in personalized medicine dealmaking 


2.1. Introduction
2.2. Personalized medicine partnering over the years
2.2.1 Biomarker partnering over the years
2.2.2 Companion diagnostic partnering over the years
2.2.3 Pharmacogenomics partnering over the years
2.3. Big pharma personalized medicine dealmaking activity
2.3.1 Big pharma biomarker, companion diagnostic and pharmacogenomics dealmaking activity
2.4. Most active in personalized medicine
2.5. Personalized medicine partnering by deal type
2.5.1 Biomarker partnering by deal type
2.5.2 Companion diagnostic partnering by deal type
2.5.3 Pharmacogenomics partnering by deal type
2.6. Personalized medicine partnering by disease type
2.6.1 Biomarker partnering by disease type
2.6.2 Companion diagnostic partnering by disease type
2.6.3 Pharmacogenomics partnering by disease type
2.7 Average deal terms for personalized medicine
2.7.1 Personalized medicine headline values by year
2.7.2 Personalized medicine upfront payments by year
2.7.3 Personalized medicine milestone payments by year
2.7.4 Personalized medicine royalty rates by year


Chapter 3 – Leading biomarker deals 


3.1. Introduction
3.2. Top biomarker deals by value


Chapter 4 – Leading companion diagnostic deals 


4.1. Introduction
4.2. Top companion diagnostic deals by value


Chapter 5 – Leading pharmacogenomics deals 


5.1. Introduction
5.2. Top pharmacogenomics deals by value


Chapter 6 – Big pharma personalized medicine deals 


6.1. Introduction
6.2. How to use big pharma personalized medicine partnering deals
6.3. Big pharma personalized medicine partnering company profiles
Abbott
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
Daiichi Sankyo
Eisai
Eli Lilly
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Takeda
Teva
UCB


Chapter 7 – Biomarker contracts dealmaking directory 


7.1. Introduction

7.2. Biomarker partnering deals with a contract available by company A-Z

7.3. Biomarker partnering deals with a contract available by by deal type

7.4. Biomarker partnering deals with a contract available by therapy type


Chapter 8 – Companion diagnostic contracts dealmaking directory 


8.1. Introduction

8.2. Companion diagnostic partnering deals with a contract available by company A-Z

8.3. Companion diagnostic partnering deals with a contract available by deal type

8.4. Companion diagnostic partnering deals with a contract available by therapy area

Chapter 9 – Pharmacogenomics contracts dealmaking directory 


9.1. Introduction

9.2. By Company A-Z

9.3. By deal type

9.4. By therapy type


Chapter 10 – Personalized medicine dealmaking directory by specific technology type 


Personalized medicine
Pharmacogenomics
Biomarkers
Companion Diagnostics


Chapter 11 – Personalized medicine partnering resource center 


11.1. Online personalized medicine partnering
11.2. Personalized medicine partnering events
11.3. Further reading on personalized medicine dealmaking


About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from Current Partnering
Order Form – Upgrades to subscription access products
Order Form – Reports


Table of figures 

Figure 1: Personalized medicine partnering since 2009
Figure 2: Biomarker partnering since 2009
Figure 3: Companion diagnostics partnering since 2009
Figure 4: Pharmacogenomics partnering since 2009
Figure 5: Big pharma – top 50 – personalized medicine deals 2009 to 2014
Figure 6: Big pharma personalized medicine deal frequency – 2009 to 2014
Figure 7: Big pharma – top 50 – biomarker, companion diagnostic and pharmacogenomics deals 2009 to 2014
Figure 8: Big pharma biomarker deal frequency – 2009 to 2014
Figure 9: Big pharma companion diagnostic deal frequency – 2009 to 2014
Figure 10: Big pharma pharmacogenomics deal frequency – 2009 to 2014
Figure 11: Most active in personalized medicine partnering 2009-2014
Figure 12: Most active in biomarkers partnering 2009-2014
Figure 13: Most active in companion diagnostic partnering 2009-2014
Figure 14: Most active in pharmacogenomics partnering activity 2009-2014
Figure 15: Personalized medicine partnering by deal type since 2009
Figure 16: Biomarker partnering by deal type since 2009
Figure 17: Companion diagnostics partnering by deal type since 2009
Figure 18: Pharmacogenomics partnering by deal type since 2009
Figure 19: Personalized medicine partnering by disease type since 2009
Figure 20: Personalized medicine partnering by oncology target since 2009
Figure 21: Biomarker partnering by disease type since 2009
Figure 22: Biomarker partnering by oncology target since 2009
Figure 23: Companion diagnostics partnering by disease type since 2009
Figure 24: Companion diagnostic partnering by oncology target since 2009
Figure 25: Pharmacogenomics partnering by disease type since 2009
Figure 26: Pharmacogenomics partnering by oncology target since 2009
Figure 27: Personalized medicine deals with a headline value by year- 2014
Figure 28: Personalized medicine deals with a headline value by year- 2013
Figure 29: Personalized medicine deals with a headline value by year- 2012
Figure 30: Personalized medicine deals with a headline value by year- 2011
Figure 31: Personalized medicine deals with a headline value by year- 2010
Figure 32: Personalized medicine deals with a headline value by year- 2009
Figure 33: Personalized medicine deals by headline value distribution in 2014
Figure 34: Personalized medicine deals by headline value distribution in 2013
Figure 35: Personalized medicine deals by headline value distribution in 2012
Figure 36: Personalized medicine deals by headline value distribution in 2011
Figure 37: Personalized medicine deals by headline value distribution in 2010
Figure 38: Personalized medicine deals by headline value distribution in 2009
Figure 39: Summary median headline value by year, 2009-2014
Figure 40: Personalized medicine deals with an upfront value by year- 2014
Figure 41: Personalized medicine deals with an upfront value by year- 2013
Figure 42: Personalized medicine deals with an upfront value by year- 2012
Figure 43: Personalized medicine deals with an upfront value by year- 2011
Figure 44: Personalized medicine deals with an upfront value by year- 2010
Figure 45: Personalized medicine deals with an upfront value by year- 2009
Figure 46: Personalized medicine deals by upfront value distribution in 2014
Figure 47: Personalized medicine deals by upfront value distribution in 2013
Figure 48: Personalized medicine deals by upfront value distribution in 2012
Figure 49: Personalized medicine deals by upfront value distribution in 2011
Figure 50: Personalized medicine deals by upfront value distribution in 2010
Figure 51: Personalized medicine deals by upfront value distribution in 2009
Figure 52: Summary median upfront value by year, 2009-2014
Figure 53: Personalized medicine deals with a milestone value by year- 2014
Figure 54: Personalized medicine deals with a milestone value by year- 2013
Figure 55: Personalized medicine deals with a milestone value by year- 2012
Figure 56: Personalized medicine deals with a milestone value by year- 2011
Figure 57: Personalized medicine deals with a milestone value by year- 2010
Figure 58: Personalized medicine deals with a milestone value by year- 2009
Figure 59: Personalized medicine deals by milestone distribution in 2014
Figure 60: Personalized medicine deals by milestone distribution in 2013
Figure 61: Personalized medicine deals by milestone distribution in 2012
Figure 62: Personalized medicine deals by milestone distribution in 2011
Figure 63: Personalized medicine deals by milestone distribution in 2010
Figure 64: Personalized medicine deals by milestone distribution in 2009
Figure 65: Personalized medicine deals with a royalty rate value by year- 2014
Figure 66: Personalized medicine deals with a royalty rate value by year- 2013
Figure 67: Personalized medicine deals with a royalty rate value by year- 2012
Figure 68: Personalized medicine deals with a royalty rate value by year- 2011
Figure 69: Personalized medicine deals with a royalty rate value by year- 2010
Figure 70: Personalized medicine deals with a royalty rate value by year- 2009
Figure 71: Summary median royalty rate by year, 2009-2014
Figure 72: Top biomarker deals by value since 2009
Figure 73: Top companion diagnostic deals by value since 2009
Figure 74: Top pharmacogenomics deals by value since 2009
Figure 75: Online partnering resources
Figure 76: Forthcoming partnering events